The Western Pacific Regional Framework to End TB: overview and critical reflection.

K H Oh, F Morishita, K Rahevar, R-P Yadav, H T G Tran, G B Marks, M C Raviglione, B J Marais
{"title":"The Western Pacific Regional Framework to End TB: overview and critical reflection.","authors":"K H Oh, F Morishita, K Rahevar, R-P Yadav, H T G Tran, G B Marks, M C Raviglione, B J Marais","doi":"10.5588/ijtldopen.24.0608","DOIUrl":null,"url":null,"abstract":"<p><p>Despite notable progress, TB remains a critical public health challenge in the Western Pacific Region. To address this, the WHO developed the Western Pacific Regional Framework to End TB, which aligns with global health targets, such as the End TB Strategy and the Sustainable Development Goals. Here, we critically review the Framework, highlighting its strengths and ongoing challenges, with suggestions as to how it might adapt. Although the Framework offers a comprehensive strategy for reducing the TB burden, its success depends on effective implementation across diverse socio-economic contexts. Key obstacles include undiagnosed infectious TB cases, limited healthcare infrastructure, persistent inequities in access to TB services, and drug-resistant TB. The COVID-19 pandemic exacerbated these challenges, disrupting TB services and delaying progress towards 2030 targets. The Framework's reliance on multisectoral partnerships and innovative technologies presents opportunities but requires substantial political commitment, sustained funding and system-wide health reforms. Additionally, gaps remain in addressing social determinants of TB. Ensuring equity, maintaining political will, and fostering international collaboration are essential to overcoming these barriers. Continuous evaluation and adaptation will be crucial in ensuring the Framework's effectiveness in eliminating TB in the Region by 2030.</p>","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 2","pages":"64-72"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827672/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJTLD open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5588/ijtldopen.24.0608","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Despite notable progress, TB remains a critical public health challenge in the Western Pacific Region. To address this, the WHO developed the Western Pacific Regional Framework to End TB, which aligns with global health targets, such as the End TB Strategy and the Sustainable Development Goals. Here, we critically review the Framework, highlighting its strengths and ongoing challenges, with suggestions as to how it might adapt. Although the Framework offers a comprehensive strategy for reducing the TB burden, its success depends on effective implementation across diverse socio-economic contexts. Key obstacles include undiagnosed infectious TB cases, limited healthcare infrastructure, persistent inequities in access to TB services, and drug-resistant TB. The COVID-19 pandemic exacerbated these challenges, disrupting TB services and delaying progress towards 2030 targets. The Framework's reliance on multisectoral partnerships and innovative technologies presents opportunities but requires substantial political commitment, sustained funding and system-wide health reforms. Additionally, gaps remain in addressing social determinants of TB. Ensuring equity, maintaining political will, and fostering international collaboration are essential to overcoming these barriers. Continuous evaluation and adaptation will be crucial in ensuring the Framework's effectiveness in eliminating TB in the Region by 2030.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Assessing the accuracy of the updated Fujifilm SILVAMP TB LAM II assay between lot numbers. Closing the gaps in childhood TB detection. Comparative efficacy of tetracyclines against isolates of Mycobacterium avium complex. Efficacy and safety data on pretomanid for drug-resistant TB. Ending the TB epidemic - what can we learn from the HIV epidemic?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1